[{"address1": "712 Vista Boulevard", "address2": "Suite 305", "city": "Waconia", "state": "MN", "zip": "55387", "country": "United States", "phone": "952 479 1196", "website": "https://www.panbela.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.", "age": 55, "title": "CEO, President & Director", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 527000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan  Horvath", "age": 64, "title": "VP of Finance, CFO, Secretary & Treasurer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 333000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tammy  Groene", "title": "Vice President of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Elizabeth  Bruckheimer Ph.D.", "title": "VP & Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.23, "open": 1.23, "dayLow": 1.08, "dayHigh": 1.2799, "regularMarketPreviousClose": 1.23, "regularMarketOpen": 1.23, "regularMarketDayLow": 1.08, "regularMarketDayHigh": 1.2799, "beta": 0.825, "forwardPE": -0.03228621, "volume": 832539, "regularMarketVolume": 832539, "averageVolume": 916609, "averageVolume10days": 373650, "averageDailyVolume10Day": 373650, "bidSize": 1000, "askSize": 1000, "marketCap": 3864243, "fiftyTwoWeekLow": 1.06, "fiftyTwoWeekHigh": 477.0, "fiftyDayAverage": 6.4974, "twoHundredDayAverage": 35.36245, "currency": "USD", "enterpriseValue": 4571586, "floatShares": 256233, "sharesOutstanding": 3481300, "sharesShort": 106974, "sharesShortPriorMonth": 46356, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0307, "heldPercentInsiders": 6.0000002e-05, "heldPercentInstitutions": 0.00597, "shortRatio": 0.07, "shortPercentOfFloat": 0.0307, "bookValue": -16.574, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -23524000, "trailingEps": -157.02, "forwardEps": -34.38, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "PBLA", "underlyingSymbol": "PBLA", "shortName": "Panbela Therapeutics, Inc.", "longName": "Panbela Therapeutics, Inc.", "firstTradeDateEpochUtc": 1483453800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "65af0cc9-415e-3d25-afda-b689cbccb358", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.11, "targetHighPrice": 500.0, "targetLowPrice": 320.0, "targetMeanPrice": 410.0, "targetMedianPrice": 410.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 907000, "totalCashPerShare": 3.538, "totalDebt": 5194000, "quickRatio": 0.119, "currentRatio": 0.212, "returnOnAssets": -1.91868, "freeCashflow": -12340250, "operatingCashflow": -27172000, "financialCurrency": "USD", "trailingPegRatio": null}]